Allergan agrees to buy Zeltiq for about $2.48 billion

Allergan Plc on Monday said it would buy Zeltiq Aesthetics Inc for about $2.48 billion to gain access to its flagship body contouring technology.

The Botox maker agreed to pay $56.50 per Zeltiq share, or a premium of 14.4 percent to the company's Friday close.

(Reporting by Natalie Grover in Bengaluru; Editing by Shounak Dasgupta)